---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008314"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:03:16.493025+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "low"
source: SEC EDGAR
---

# Atossa reports preliminary cash balance of ~$40M, limited other details

## Summary
- Estimated cash and cash equivalents of ~$40M as of Dec 31, 2025, preliminary and unaudited.
- No quarterly earnings, revenue, or operational results were disclosed in this filing.
- Updated corporate presentation likely focuses on (Z)-Endoxifen development strategy per forward-looking statements.
- Cash estimate subject to finalization of year-end financial closing procedures.

## SEC filing metadata
- accession: 0001193125-26-008314
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/0001193125-26-008314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526008314/atos-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008314
- JSON: https://secwatch.observer/filing/0001193125-26-008314.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.